Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

Authors:

Abstract
Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study.

This publication has 18 references indexed in Scilit: